Several leading In Vitro Diagnostic (IVD) companies have posted their first-quarter results for 2026, showing mixed performance across revenue, profitability, and cash flow.

It can be seen from analysis on major blood grouping analyzer-related patent applications published in the 3 years from 2018 to 2021 that benefited from the basically stable original technologies of the industry; domestic enterprises have continuously increased R&D inputs, constantly improved technical innovation capability, made breakthroughs in many technologies, and developed a batch of core components of instruments with independent intellectual property rights through follow-on R&D strategy.

Swift Biosciences has partnered with LGC Biosearch Technologies to incorporate Swift's targeted sequencing technology into LGC's kits and service offerings for the worldwide ag-bio market.

Natera reported after the close of the market on Wednesday that its fourth quarter 2019 revenues grew 24 percent year over year.

Swift Biosciences has partnered with LGC Biosearch Technologies to incorporate Swift's targeted sequencing technology into LGC's kits and service offerings for the worldwide ag-bio market.

Illumina has asked a US Court for a preliminary injunction to prevent BGI from distributing sequencers in the US to a handful of labs on a no-cost trial basis.

Fluidigm said on Wednesday that it has completed the acquisition of InstruNor, a privately held, Oslo-based provider of integrated sample preparation systems for flow and mass cytometry.

The US International Trade Commission has upheld a judge's previous determination that certain microfluidic products imported by Bio-Rad Laboratories indirectly infringe patents held by 10x Genomics.

BioMérieux reported today that its fourth quarter revenues rose 11 percent year over year driven by sales of molecular biology reagents and microbiology instruments, as well as a strong dynamic in Asia Pacific.

Adaptive Biotechnologies reported after the close of the market on Wednesday that its fourth quarter revenues increased 41 percent year over year.

Lucid Diagnostics announced recently it has entered a research agreement with the Fred Hutchinson Cancer Research Center to evaluate the center's Barrett's Esophagus progression biomarkers using Lucid's EsoCheck Esophageal Cell Collection De

Novacyt said recently that its molecular test for the COVID-19 virus has received CE marking.